BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...when Novartis’ serelaxin, a recombinant form of RLN2...
...appears to be a pegylated formulation of RLN2...
...giving it a longer half-life than wild-type RLN2...
BioCentury | Nov 18, 2019
Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

...2.6 million shares in a follow-on. Targets: CHRM1 (HM1) - Muscarinic acetylcholine receptor M1; CHRM2 (H2...
BioCentury | Jun 18, 2019
Distillery Therapeutics

RLN2 injections to treat shoulder arthrofibrosis

...DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Injections of RLN2 could help treat shoulder arthrofibrosis, which manifests as...
...joint range of motion. In a rat model of immobilization-induced shoulder arthrofibrosis, intra-articular injections of RLN2...
...function. Following intra-articular injection, the synovial half-life of RLN2 was 0.62 hours. TARGET/MARKER/PATHWAY: Relaxin 2 (RLN2; H2...
BioCentury | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

...Perceptive Advisors, Nextech Invest and GV. Targets: CHRM1 (HM1) - Muscarinic acetylcholine receptor M1; CHRM2 (H2...
BioCentury | Apr 15, 2019
Distillery Therapeutics

Inhibitors of allergen-specific IgE responses for peanut allergy

...INDICATION: Allergy Cell culture studies identified two covalent, heterobivalent inhibitors of IgE responses against Ara h2...
...could help treat peanut allergy. The covalent heterobivalent inhibitors consist of an epitope from Ara h2...
BioCentury | Mar 18, 2019
Financial News

Karuna looks past schizophrenia with $68M series B

...series A round, announced August 2018. Targets: CHRM1 (HM1) - Muscarinic acetylcholine receptor M1; CHRM2 (H2...
BioCentury | Feb 28, 2019
Company News

Akcea gains as Novartis exercises option for CV risk reduction therapy

...risk reduction. In 2017, the pharma discontinued development of serelaxin (RLX030) after the recombinant human RLN2...
...on Feb. 25. Targets: APOA1 (apo(a)) - Apolipoprotein A-1; LPA - Lipoprotein(a); RLN2 (H2) - Relaxin 2...
BioCentury | Feb 25, 2019
Company News

Akcea gains as Novartis exercises option for CV risk reduction therapy

...risk reduction. In 2017, the pharma discontinued development of serelaxin (RLX030) after the recombinant human RLN2...
...$61.67 on Monday. Targets: APOA1 (apo(a)) - Apolipoprotein A-1; LPA - Lipoprotein(a); RLN2 (H2) - Relaxin 2 Sandi...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...coactivator 1-α PLK1 (STPK13) - Polo-like kinase 1 RAD51 - RAD51 homolog RNASEH2 - Ribonuclease H2...
BioCentury | Aug 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

...help treat breast cancer Boston University Distillery Therapeutics Breast cancer; cervical cancer; colorectal cancer Ribonuclease H2...
Items per page:
1 - 10 of 216